Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:0
članak: 10 od 134  
Back povratak na rezultate
Medicinski pregled
2018, vol. 71, br. 3-4, str. 89-95
jezik rada: engleski
vrsta rada: originalan članak
doi:10.2298/MPNS1804089T


Stereološka analiza androgenih receptora kod karcinoma i benigne hiperplazije prostate
aUniversity of Novi Sad, Faculty of Medicine, Department of Pathology + Clinical Centre of Vojvodina, Centre for Pathology and Histology, Novi Sad
bUniversity of Novi Sad, Faculty of Medicine, Department of Surgery + Clinical Centre of Vojvodina, Clinic of Urology, Novi Sad
cUniversity of Novi Sad, Faculty of Medicine, Department of Histology and Embryology

e-adresa: sandra.trivunic-dajko@mf.uns.ac.rs

Sažetak

Uvod. Androgeni preko androgenih receptora utiču na ćelijski rast i funkciju, proliferaciju, diferencijaciju, apoptozu, lipidni metabolizam i sekretornu aktivnost prostate i na razvoj i progresiju karcinoma prostate. Karcinom prostate, kao i njegovo primarno žlezdano tkivo je pod uticajem hormona i ta činjenica je iskorištena u terapijske svrhe. Antiandrogena terapija se sprovodi kod pacijenata sa metastatskim karcinomom prostate, upravo sa ciljem da blokira dejstvo androgena. Imunohistohemijskom analizom androgenih receptora u tkivu prostate sa karcinomom, možemo da pretpostavimo kako će tumor reagovati na datu antiandrogenu terapiju, u odnosu na to da li su androgen-pozitivni i androgen-negativni, ili hormonski rezistentni tumori. Saznanja o zastupljenosti androgenih receptora u tkivu tumora, mogla bi da posluže kao prognostički indikator, u patohistološkoj analizi. Cilj ove studije je stereološka evaluacija ekspresije androgenih receptora kod pacijenata sa karcinomom prostate i benignom hiperplazijom, pre sprovedene terapije. Materijal i metode. Imunohistohemijska analiza je sprovedena upotrebom monoklonalnog androgen-receptor441 antitela. Stereološki je procenjivano prisustvo i intenzitet androgenih receptora kod 195 pacijenata sa benignom hiperplazijom (165) i karcinomom prostate (30), uz upotrebu multinamenskog Vajbelovog (Weibel) testnog sistema M-42. Materijal je dobijen biopsijom iglom ili transuretralnom resekcijom prostate. Rezultati. Sve sekretorne ćelije kod pacijenata sa benignom hiperplazijom su bile androgen-pozitivne, dok su kod pacijenata sa karcinomom prostate, svi tumori mahom bili androgen-pozitivni, ali pojedini sa fokusima negativnosti. Dobijena je negativna korelacija sa Glisonovim skorom (Gleason) i International Society of Urological Pathology gradus grupom, koja nije statistički značajna. Zaključak. Rezultati studije stereološke analize androgenih receptora ukazuje da je karcinom prostate pre terapije androgen-zavisan; ima visok stepen ekspresije androgenih receptora, mada nešto manji u odnosu na benignu hiperplaziju.

Ključne reči

Reference

Abrams, D., Facer, P., Bishop, A.E., Polak, J.M. (1994) A computer-assisted stereological quantification program: Openstereo. Microscopy Research and Technique, 29(3): 240-247
Attard, G., Cooper, C.S., de Bono, J.S. (2009) Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?. Cancer Cell, 16(6): 458-462
Botticelli, A.R., Pitino, A., Botticelli, D. (2002) Expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica, 94(2): 107-11
Collan, Y. (1983) Stereology and morphometry in pathology: An introduction. Acta Stereol, 2, str. 207-13
Gordetsky, J., Epstein, J. (2016) Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic Pathology, 11(1): 25-33
Gudović, R., Matavulj, M., Stefanović, N., Lozanov-Crvenković, Z. (1994) Osnovi stereologije. Folia anatomica, 21/22, str. 1-25
Hanahan, D., Weinberg, R.A. (2011) Hallmarks of cancer: The next generation. Cell, 144(5): 646-674
Hansson, J., Abrahamsson, P.-A. (2001) Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Annals of Oncology, 12(suppl 2): S145-S152
Heinlein, C.A., Chang, C. (2004) Androgen Receptor in Prostate Cancer. Endocrine Reviews, 25(2): 276-308
Horwich, A., Parker, C., de Reijke, T., Kataja, V. (2013) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24(suppl 6): vi106-vi114
Hudes, G.R. (2002) Signaling inhibitors in the treatment of prostate cancer. Investigational New Drugs, 20(2): 159-172
Huggins, C., Hodges, C.V. (2002) Studies on Prostatic Cancer. Journal of Urology, str. 9-12
Li, R., Wheeler, T., Dai, H., Frolov, A., Thompson, T., Ayala, G. (2004) High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate. American Journal of Surgical Pathology, 28(7): 928-934
Milovanović, L., Milovanović, B. (2012) Kvalitet života i rezultati lečenja bolesnika s nemetastatskim karcinomom prostate nakon primene totalne androgene blokade samostalno i s radioterapijom. Srpski arhiv za celokupno lekarstvo, vol. 140, br. 7-8, str. 462-468
Noordzij, M.A., Bogdanowicz, J.F.A.T., van Krimpen, C., van der Kwast, T.H., van Steenbrugge, G.J. (1997) The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. Journal of Urology, 158(5): 1880-1885
Osman, W.M., Abd, E.A.R.M., Abou, G.H.H. (2013) DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: A possible role in carcinogenesis. Journal of the Egyptian National Cancer Institute, 25(4): 223-230
Poelaert, F., van Praet, C., Beerens, A., de Meerleer, G., Fonteyne, V., Ost, P., Lumen, N. (2015) The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study. BioMed Research International, 2015: 1-8
Qiu, Y., Leuschner, I., Braun, P.M. (2008) Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. Asian Journal of Andrology, 10(6): 855-863
Renzo, A., Botticelli, A., Pitino, A., Botticelli, A.R., Zaffe, D. (2002) Prognostic relationship between immunohistochemical expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica, 94(2): 109-12
Segawa, N., Mori, I., Utsunomiya, H., Nakamura, M., Nakamura, Y., Shan, L., Kakudo, K., Katsuoka, Y. (2001) Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathology International, 51(6): 452-459
Takeda, H., Akakura, K., Masai, M., Akimoto, S., Yatani, R., Shimazaki, J. (1996) Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer, 77(5): 934-940
Tamburrino, L., Salvianti, F., Marchiani, S., Pinzani, P., Nesi, G., Serni, S., Forti, G., Baldi, E. (2012) Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens. Steroids, 77(10): 996-1001
Teba, F., Martín, R., Gómez, V., Santamaría, L. (2005) Stereological Study of Mean Nuclear Volume Weighted by Volume in Normal Prostate, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma. u: Li, Jonathan J.; Li, Sara A.; Llombart-Bosch, Antonio [ur.] Hormonal Carcinogenesis IV, Boston: Springer Nature America, Inc, str. 329-335
Theodoropoulos, V.E., Tsigka, A., Mihalopoulou, A., Tsoukala, V., Lazaris, A.C., Patsouris, E., Ghikonti, I. (2005) Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: Prognostic implications. Urology, 66(4): 897-902
Trivunić, S., Budakov, P., Vučković, N., Živojinov, M. (2007) Morphological parameters of prostatic adenocarcinoma. Medicinski pregled, vol. 60, br. 11-12, str. 549-552
Vojinov, S., Levakov, I., Jeremić, D., Živojinov, S., Marušić, G. (2011) Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade. Vojnosanitetski pregled, vol. 68, br. 4, str. 321-326
Wein, A.J., Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A. (2015) Development, molecular biology, and physiology of the prostate. u: Berman D.M. [ur.] Campbell-Walsh urology, Philadelphia: Elsevier Saunders, p. 2393-2425
Wein, A.J., Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A. (2015) Hormonal therapy for prostate cancer. u: Berman D.M. [ur.] Campbell-Walsh urology, Philadelphia: Elsevier Saunders, p. 2786-804
Wetherill, Y.B., Petre, C.E., Monk, K.R., Puga, A., Knudsen, K.E. (2002) The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adeno-carcinoma. Mol Cancer Ther., 1(7): 515-24
Wied, G.L., Bartels, P.H., Bibbo, M., Dytch, H.E. (1989) Image analysis in quantitative cytopathology and histopathology. Human Pathology, 20(6): 549-571
Wikström, P., Marusic, J., Stattin, P., Bergh, A. (2009) Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate, 69(8): 799-809
World Health Organization (2016) World health statistics 2016: Monitoring health for the SDGs sustainable development goals. Geneva
Zhou, M., Netto, G., Epstein, J. (2012) Uropathology. Philadelphia: Saunders, p. 52-127